Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00481585 · ClinicalTrials.gov registry record
The Biology of Claudin 3 in Primary Human Mammary Epithelial Cell Culture
A clinical trial, sponsored by Hackensack Meridian Health.
- Terminated
- Registry status
- 13
- Enrollment target
NCT00481585 is a clinical trial that was terminated before completion, run by Hackensack Meridian Health. The registered enrollment target is 13 participants.
The verdict
NCT00481585 was terminated before completion, sponsored by Hackensack Meridian Health.
- TERMINATED
- Registry status
- 13 participants
- Enrollment target
Study Summary
The objective of the present study is to determine whether or not primary human mammary epithelial cells are competent for use in molecular studies of transepithelial electrophysiology focusing on the function of the tight junction protein claudin 3. Human breast Tissue will be removed from mastectomy specimens and used as a source to generate epithelial cells for study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2007-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00481585
The ClinicalTrials.gov registry entry for NCT00481585 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00481585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00481585 about?
NCT00481585 is a clinical study titled "The Biology of Claudin 3 in Primary Human Mammary Epithelial Cell Culture". The objective of the present study is to determine whether or not primary human mammary epithelial cells are competent for use in molecular studies of transepithelial electrophysiology focusing on the function of the tight junction protein claudin 3. Human breast Tissue will be removed from mastect...
What is the current status of trial NCT00481585?
This trial is currently terminated. The enrollment target is 13 participants. The study started on 2007-05.
Who is sponsoring clinical trial NCT00481585?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.